K.V. Kowdley

1399 12-WEEK INTERFERON-FREE REGIMEN OF ABT-450/R +ABT-333 +RIBAVIRIN ACHIEVED SVR12 IN MORE THAN 90% OF TREATMENT-NAIVE HCV GENOTYPE-1-INFECTED SUBJECTS AND 47% OF PREVIOUS NON-RESPONDERS

F. Poordad, E. Läwitz, K.V. Kowdley et al. · Journal of Hepatology · 2012 · 65 citations

Viral Hepatitis, Immunodeficiencies, Immunology +9

3 SAFETY AND EFFICACY OF INTERFERON-FREE REGIMENS OF ABT-450/r, ABT-267, ABT-333 +/− RIBAVIRIN IN PATIENTS WITH CHRONIC HCV GT1 INFECTION: RESULTS FROM THE AVIATOR STUDY

K.V. Kowdley, E. Läwitz, F. Poordad et al. · Journal of Hepatology · 2013 · 56 citations · Full text

Viral Hepatitis, Antiviral Drug Development, Antiviral Therapy +6

13 A 12-WEEK INTERFERON-FREE REGIMEN OF ABT-450/R, ABT-072, AND RIBAVIRIN WAS WELL TOLERATED AND ACHIEVED SUSTAINED VIROLOGIC RESPONSE IN 91% TREATMENT-NAIVE HCV IL28B-CC GENOTYPE-1-INFECTED SUBJECTS

E. Läwitz, F. Poordad, K.V. Kowdley et al. · Journal of Hepatology · 2012 · 43 citations

Viral Hepatitis, Immunology, Antiviral Therapy +8

P0775 : Final evaluation of 955 HCV patients treated with 12 week regimens containing sofosbuvir +/- simeprevir in the trio network: Academic and community treatment of a real-world, heterogeneous population

Doug Dieterich, Bruce R. Bacon, Steven L. Flamm et al. · Journal of Hepatology · 2015 · 43 citations

Hcv Patients, Viral Persistence, Trio Network +11

Durable HBeAg and HBsAg seroconversions after lamivudine for chronic hepatitis B (CHB)

Eugene R. Schiff, J Cianciara, K.V. Kowdley et al. · Journal of Hepatology · 2000 · 31 citations

Hbsag Seroconversions, Hepatology, Viral Hepatitis +9